Physician profile
Michael P Kellam
NPI 1689789950
$9,580.77
in general payments reported to CMS, 2019-2025
71 companies · $1,592 in 2025
The $1,592 reported for 2025 was more than what 79% of Sleep Medicine (Psychiatry & Neurology) providers received nationally (typical 2025 total: $337).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,536 · 2020: $33.77 · 2021: $487 · 2022: $1,401 · 2023: $2,438 · 2024: $2,093 · 2025: $1,592.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,957 · Consulting Fee: $150 · Education: $16.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,956.67 |
| Consulting Fee | $150.00 |
| Education | $16.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $1,592.15 | 2019-2025 | Rytary, Crexont |
| Abbvie INC. | $749.78 | 2021-2025 | |
| Biogen, INC. | $444.45 | 2020-2025 | Tysabri, Vumerity, Skyclarys |
| Lilly USA, LLC | $402.34 | 2022-2025 | Emgality, Amyvid, Kisunla |
| Ucb, INC. | $361.33 | 2021-2025 | Rystiggo, Fintepla, Briviact |
| Sk Life Science, INC. | $314.76 | 2021-2025 | Xcopri |
| Teva Pharmaceuticals USA, INC. | $247.47 | 2022-2025 | Austedo Xr, Austedo Xr, Austedo |
| Genentech USA, INC. | $227.45 | 2022-2025 | Enspryng, Ocrevus, Ocrevus Zunovo |
| Itamar Medical INC | $222.73 | 2023 | Watchpatone |
| Abbott Laboratories | $219.07 | 2023-2025 | Infinity |
| Grifols USA, LLC | $208.15 | 2021-2025 | Gamunex-C |
| Emd Serono, INC. | $205.32 | 2023-2025 | Mavenclad, Mavenclad |
| Eisai INC. | $196.89 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $189.31 | 2021-2025 | |
| Inspire Medical Systems, INC. | $187.21 | 2024 | Inspire |
Show all 71 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Kellam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.